Meridian Bioscience, Inc. (NASDAQ: VIVO - News) has completed the purchase of all the outstanding capital stock of the Bioline group of companies consisting of Bioline Ltd (UK), Bioline GmbH (Germany), Bioline (Aust) Pty Ltd (Australia), Bioline Reagents Ltd, and Bioline USA, Inc for $23.3 million in cash on hand.

Meridian Bioscience, Inc. (NASDAQ:VIVO - News) has received clearance from the U.S. Food and Drug Administration (FDA) for its new molecular amplification assay, illumigene™ C. difficile.

Meridian Bioscience, Inc. announced that it has submitted a 510(k) application to the United States Food and Drug Administration for marketing clearance of its new, simple molecular diagnostic test, illumigene™ C. difficile.

MedCity News recently published a Q&A with Jack Kraeutler, chief executive of Meridian Bioscience. Kraeutler talked about the promise of his company’s new generation of diagnostic tests, potential acquisitions, as well as the challenges and opportunities awaiting Meridian in 2010.